Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells

Anticancer drug resistance is a significant impediment in current cancer treatment. Extracellular vesicles (EVs) derived from cancer cells were recently acknowledged as a critical mechanism of drug resistance, tumor progression, and metastasis. EVs are enveloped vesicles comprising a lipid bilayer that transfers various cargo, including proteins, nucleic acids, lipids, and metabolites, from an originating cell to a recipient cell. Investigating the mechanisms whereby EVs confer drug resistance is still in the early stages. In this review, I analyze the roles of EVs derived from triple-negative breast cancer cells (TNBC-EVs) in anticancer drug resistance and discuss strategies to overcome TNBC-EV-mediated drug resistance.

Automated summary

Anticancer drug resistance is a major challenge in cancer treatment, and extracellular vesicles (EVs) derived from cancer cells have been identified as a crucial mechanism for drug resistance, tumor progression, and metastasis. EVs, which consist of a lipid bilayer, can transfer various substances including proteins, nucleic acids, lipids, and metabolites from the originating cell to the recipient cell. The investigation of EVs' role in drug resistance is still at an early stage. This review analyzes the involvement of EVs derived from triple-negative breast cancer cells (TNBC-EVs) in anticancer drug resistance and discusses strategies to overcome TNBC-EV-mediated drug resistance.